+0.77%
Today
Loading 1D prices…
Company profile
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
Sector
Health Care
Industry
Surgical & Medical Instruments & Apparatus
Exchange
Nasdaq
Display currency
USD
Location
Irvine, CA, United States
Employees
76
Fiscal year end
1231
CIK
1778922
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| BVSBioventus Inc. Class A Common Stock | $886.6M | $568.1M | +4.00% | $0.33 | -0.61% | Buy |
| SIBNSI-BONE Inc. Common Stock | $823.8M | $200.9M | -9.41% | -$0.44 | +0.38% | Buy |
| IRMDiRadimed Corporation Common Stock | $1.1B | $83.8M | +26.82% | $1.75 | +0.43% | Buy |
| BBNXBeta Bionics Inc. Common Stock | $745.5M | $100.3M | -73.02% | -$1.81 | -0.06% | Buy |
| PRCTPROCEPT BioRobotics Corporation Common Stock | $1.2B | $308.1M | -0.03% | -$1.72 | +1.49% | Hold |